Moderna's Investigational Therapeutic mRNA-3705 in FDA's START Pilot Program
Thursday, 6 June 2024, 08:28
Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
Moderna's investigational therapeutic mRNA-3705 has been chosen by the U.S. Food & Drug Administration to participate in the START Pilot Program. This selection highlights the potential of mRNA-3705 in addressing Methylmalonic Acidemia, a rare genetic disorder.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.